You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address